As of May 23, 2025, UnitedHealth Group Inc's estimated intrinsic value ranges from $242.17 to $263.80 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|---|---|
Dividend Discount Model (Multi-Stage) | $242.17 | -18.4% |
Dividend Discount Model (Stable) | $263.80 | -11.1% |
Is UnitedHealth Group Inc (UNH) undervalued or overvalued?
With the current market price at $296.67, the stock appears to be moderately overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate UnitedHealth Group Inc's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 0.84 | 0.94 |
Cost of equity | 7.7% | 10.1% |
Cost of debt | 5.0% | 5.0% |
Tax rate | 21.2% | 22.6% |
Debt/Equity ratio | 0.29 | 0.29 |
After-tax WACC | 6.9% | 8.7% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
Metric | Value |
---|---|
Market Capitalization | $270035M |
Enterprise Value | $317015M |
Trailing P/E | 12.22 |
Forward P/E | 16.71 |
Trailing EV/EBITDA | 0.00 |
Current Dividend Yield | 290.40% |
Dividend Growth Rate (5Y) | 13.22% |
Debt-to-Equity Ratio | 0.29 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Dividend Discount Model (Multi-Stage) | 57% | $48.43 |
Dividend Discount Model (Stable) | 43% | $39.57 |
Weighted Average | 100% | $251.44 |
Based on our comprehensive valuation analysis, UnitedHealth Group Inc's weighted average intrinsic value is $251.44, which is approximately 15.2% below the current market price of $296.67.
Key investment considerations:
Given these factors, we believe UnitedHealth Group Inc is currently moderately overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.